V. Buffard

736 total citations · 1 hit paper
11 papers, 471 citations indexed

About

V. Buffard is a scholar working on Pharmacology, Neurology and Oncology. According to data from OpenAlex, V. Buffard has authored 11 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pharmacology, 3 papers in Neurology and 3 papers in Oncology. Recurrent topics in V. Buffard's work include Drug-Induced Adverse Reactions (3 papers), Urticaria and Related Conditions (2 papers) and Neurofibromatosis and Schwannoma Cases (2 papers). V. Buffard is often cited by papers focused on Drug-Induced Adverse Reactions (3 papers), Urticaria and Related Conditions (2 papers) and Neurofibromatosis and Schwannoma Cases (2 papers). V. Buffard collaborates with scholars based in France and United States. V. Buffard's co-authors include Pierre Duvillard, Agnès Certain, Ludovic Lacroix, E. Maubec, Pierre Saez, France Mentré, Sandrine Mansard, Xavier Duval, Isabelle Scheer-Senyarich and Julien Gelly and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Pediatric Orthopaedics and Journal of the European Academy of Dermatology and Venereology.

In The Last Decade

V. Buffard

9 papers receiving 454 citations

Hit Papers

Phase II Study of Cetuximab As First-Line Single-Drug The... 2011 2026 2016 2021 2011 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Buffard France 5 297 204 194 100 75 11 471
Amel Mebazâa Tunisia 13 176 0.6× 83 0.4× 130 0.7× 68 0.7× 89 1.2× 46 398
Anna Peroni Italy 12 137 0.5× 85 0.4× 249 1.3× 80 0.8× 160 2.1× 16 501
Michael Krathen United States 9 140 0.5× 97 0.5× 246 1.3× 160 1.6× 146 1.9× 16 472
John D. Hendrix United States 11 207 0.7× 73 0.4× 176 0.9× 20 0.2× 96 1.3× 17 421
Anne-Bénédicte Duval-Modeste France 8 366 1.2× 239 1.2× 246 1.3× 96 1.0× 33 0.4× 18 587
Pedram Geraminejad United States 5 217 0.7× 139 0.7× 165 0.9× 16 0.2× 19 0.3× 5 329
M. Vogelbruch Germany 7 56 0.2× 99 0.5× 165 0.9× 76 0.8× 46 0.6× 10 381
Maria Estela Martínez‐Escala United States 18 263 0.9× 96 0.5× 570 2.9× 144 1.4× 97 1.3× 34 706
Ziba Rahbar Iran 11 97 0.3× 75 0.4× 129 0.7× 35 0.3× 63 0.8× 19 373
A. William United States 9 113 0.4× 75 0.4× 237 1.2× 69 0.7× 46 0.6× 12 356

Countries citing papers authored by V. Buffard

Since Specialization
Citations

This map shows the geographic impact of V. Buffard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Buffard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Buffard more than expected).

Fields of papers citing papers by V. Buffard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Buffard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Buffard. The network helps show where V. Buffard may publish in the future.

Co-authorship network of co-authors of V. Buffard

This figure shows the co-authorship network connecting the top 25 collaborators of V. Buffard. A scholar is included among the top collaborators of V. Buffard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Buffard. V. Buffard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Méni, C., et al.. (2015). Treatment of Neurofibromas with a Carbon Dioxide Laser: A Retrospective Cross-Sectional Study of 106 Patients. Dermatology. 230(3). 263–268. 22 indexed citations
2.
Oro, S., C. Fite, L. Valeyrie‐Allanore, et al.. (2015). Rituximab, a new treatment for difficult‐to‐treat chronic erythema multiforme major? Five cases. Journal of the European Academy of Dermatology and Venereology. 30(7). 1140–1143. 10 indexed citations
3.
Gonzalez‐Alegre, Pedro, et al.. (2013). Exploring the Link Between Dystonia Genes and Idiopathic Scoliosis. Journal of Pediatric Orthopaedics. 33(6). e65–e66. 1 indexed citations
4.
Oro, S., J.-M. Amici, Аleksandar Ostojić, et al.. (2012). Dermatosurgery: Total Quality Management in a Dermatology Department. Dermatology. 225(3). 204–209. 3 indexed citations
5.
Maubec, E., Peter Petrow, Isabelle Scheer-Senyarich, et al.. (2011). Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. Journal of Clinical Oncology. 29(25). 3419–3426. 334 indexed citations breakdown →
6.
Buffard, V., et al.. (2011). Élastofibrome dorsal bilatéral. Annales de Dermatologie et de Vénéréologie. 139(1). 41–45. 3 indexed citations
7.
Poszepczynska-Guigné, E., et al.. (2010). Myopathie nécrosante sévère consécutive à un carcinome à cellules de Merkel. Annales de Dermatologie et de Vénéréologie. 138(2). 130–134. 7 indexed citations
8.
Bournérias, I, et al.. (2007). Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.. PubMed. 34(2). 380–5. 89 indexed citations
9.
Farhi, David, V. Buffard, & J C Roujeau. (2006). Infections aiguës des parties molles. EMC - Traité de médecine AKOS. 9(2). 1–11. 1 indexed citations
10.
Marie‐Cardine, Anne, et al.. (2005). C96 - Effet anti-prolifératif des sémaphorines 3a et 3f sur des lignées de mélanome. Annales de Dermatologie et de Vénéréologie. 132. 62–62.
11.
Buffard, V., et al.. (2004). Réactions médicamenteuses cutanées : nouveautés pharmacogénétiques. Archives de Pédiatrie. 11(5). 489–492. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026